ALIROCUMAB EFFICACY AND SAFETY IN INDIVIDUALS WITH METABOLIC SYNDROME: POOLED DATA FROM PHASE 3 TRIALS
AACE ePoster Library. HENRY R. 05/27/16; 131484; 504
Disclosure(s): Research funding: Hitachi, Eli Lilly, and Viacyte; consultant/advisory panel member: Alere, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Clin Met, Eisai, Elcelyx, Gilead, Intarcia, Isis, Janssen/Johnson & Johnson, Merck, Novo Nordisk, Sanofi-Aventis, Vivus, and Zydus.
ROBERT HENRY
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Rate & Comment (0)
{{ help_message }}
{{filter}}